Othera Pharmaceuticals Inc., a privately-held ophthalmic pharmaceutical company developing proprietary drugs to treat or prevent the three leading causes of blindness, announced today that it has raised $13 million in a Series B financing to fund further clinical development of its ophthalmic drug pipeline. The financing was led by NewSpring Ventures, Commerce Health Ventures, and included investments from Johnson & Johnson Development Corporation, Liberty Venture Partners, its existing investors and management.
